快速起效抗抑郁药物的研究进展  

Progress in the development of early-onset antidepressants

作　　者：薛瑞[1,2] 张有志[1] 邹莉波[2] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850 [2]沈阳药科大学,辽宁沈阳110016

出　　处：《中国药理学通报》2008年第12期1558-1561,共4页Chinese Pharmacological Bulletin

基　　金：国家重点基础研究发展计划(973计划)资助项目(No2007CB512307);国家高技术研究发展计划(863计划)资助项目(No2007AA02Z400)

摘　　要：目前临床使用的抗抑郁药物存在起效延迟的不足,这不仅降低了病人的依从性,还增加了其自杀的危险性。因此,如何研制出高效低毒且快速起效的抗抑郁药物成为研发热点。研究表明,选择性5-HT1A、α2自身受体拮抗剂及5-HT2A受体拮抗剂可加快5-羟色胺重摄取抑制剂及去甲肾上腺素重摄取抑制剂等抗抑郁药物的起效速度。此外,5-HT/NE双重重摄取抑制剂及5-HT/NE/DA三重重摄取抑制剂起效时间也缩短。该文将重点围绕单胺系统对抗抑郁药物起效延迟的原因及快速起效抗抑郁药物的研究进展作一综述。Existing antidepressants exhibit delayed onset of ac- tion,which can decrease the compliance of the patients and en- hance the risk of suicide. How to produce early-onset antidepressants with higher efficacy and lower adverse reactions has become a crucial point in the research of antidepressants. It has been demonstrated that selective 5-HT1A antagonist, α2 antagonist and 5-HT2A antagonist can accelerate the response of classic antidepressants. Furthermore,5-HT/NE dual reuptake inhibitor and 5-HT/NE/DA triple reuptake inhibitor can also produce early onset of action. Here, several reasons for the delayed onset of action and the progress in the development of early-onset antidepressants are reviewed.

关 键 词：抗抑郁药物 起效时间 5-HT1A受体拮抗剂 5-HT2A 受体拮抗剂 α2受体拮抗剂 双重/三重摄取抑制剂 

分 类 号：R-05[医药卫生] R749.410.53